Karen Marie Walker
Known title: Chief Technology OfficerCIK: 0002008556
Associated companies
Transaction History
| KYTX | ▲ Buy | Option Exercise | 23,998 | $116K | 12/15/2025 | View on chart |
| KYTX | ▼ Sell | Open Market | 23,998 | $293K | 12/15/2025 | View on chart |
| KYTX | ▲ Buy | Grant | 13,000 | $0 | 4/11/2025 | View on chart |
| KYTX | ▲ Buy | Option Exercise | 9,636 | $43K | 6/6/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Kyverna Reports Positive One-Year Data for Miv-cel Trials
Kyverna Therapeutics disclosed one‑year data from its Miv‑cel trials in stiff person syndrome and generalized myasthenia gravis, showing durable responses and a favorable safety profile. The CEO noted that the high disease burden supports a premium pricing strategy. These results reinforce the potential of a single‑dose therapy to reduce long‑term treatment burden.
Kyverna Reports Positive One-Year Data for Miv-cel Trials. Kyverna Therapeutics disclosed one‑year data from its Miv‑cel trials in stiff person syndrome and generalized myasthenia gravis, showing durable responses and a favorable safety profile. The CEO noted that the high disease burden supports a premium pricing strategy. These results reinforce the potential of a single‑dose therapy to reduce long‑term treatment burden.